Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 705475
                    [Title] => MSD's cholesterol-lowering drug cuts  atherosclerotic events in CKD patients
                    [Summary] => 
Global health care company MSD (known as Merck in the US and Canada) has good news for patients with chronic kidney disease (CKD).
                    [DatePublished] => 2011-07-14 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 663193
                    [Title] => FDA review backs ezetimibe and simvastatin combination
                    [Summary] => 
After a year-long review of data from the ENHANCE trial that showed no significant difference in the changes in carotid artery thickness between patients treated with ezetimibe and simvastatin, vs. simvastatin alone, the Food and Drug Administration has concluded that patients should not stop taking ezetimibe/simvastatin or any cholesterol-lowering medications.
                    [DatePublished] => 2011-03-06 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 636431
                    [Title] => Hearty news from MSD
                    [Summary] => 
A new investigational study of Ezetimibe/Simvastatin, the cholesterol-lowering medicine from MSD (known as Merck in US and Canada) showed that at dosage of 10/20 mg, it reduced the incidence of first major vascular events  defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure  by a highly statistically significant 16.1 percent compared to placebo (p=0.0010).
                    [DatePublished] => 2010-12-07 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 38320
                    [Title] => Fluvastatin XL cuts LDL level with less myalgia
                    [Summary] => 
            
                    [DatePublished] => 2008-01-13 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 242152
                    [Title] => CAIs: Reaching optimal cholesterol goals
                    [Summary] => A new class of lipid-lowering therapy could make it easier for patients with high cholesterol levels to reach their optimal cholesterol goals.


Such was the good news relayed by Dr. Werner Katzmann, Ph.D., Far East regional medical director of the Schering-Plough Research Institute, in a lecture during the joint annual convention of the Philippine Society of Hypertension and Philippine Lipid Society recently. 


                    [DatePublished] => 2004-03-11 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [5] => Array
                (
                    [ArticleID] => 239583
                    [Title] => Lowering ‘LDL-C’ gets a boost with breakthrough drug
                    [Summary] => A new drug that will reinforce physicians’ existing therapeutic tools in lowering a patient’s low-density lipoprotein (LDL-C) or the bad cholesterol, is now out in the market. 


Ezetimibe, launched by Schering-Plough Phils. Inc., has been shown to have a clinically significant supplementary effect when used with a statin, reducing LDL-C by an additional 25 percent. 


                    [DatePublished] => 2004-02-19 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

EZETIMIBE

Array
(
    [results] => Array
        (
            [0] => Array
                (
                    [ArticleID] => 705475
                    [Title] => MSD's cholesterol-lowering drug cuts  atherosclerotic events in CKD patients
                    [Summary] => 
Global health care company MSD (known as Merck in the US and Canada) has good news for patients with chronic kidney disease (CKD).
                    [DatePublished] => 2011-07-14 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [1] => Array
                (
                    [ArticleID] => 663193
                    [Title] => FDA review backs ezetimibe and simvastatin combination
                    [Summary] => 
After a year-long review of data from the ENHANCE trial that showed no significant difference in the changes in carotid artery thickness between patients treated with ezetimibe and simvastatin, vs. simvastatin alone, the Food and Drug Administration has concluded that patients should not stop taking ezetimibe/simvastatin or any cholesterol-lowering medications.
                    [DatePublished] => 2011-03-06 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [2] => Array
                (
                    [ArticleID] => 636431
                    [Title] => Hearty news from MSD
                    [Summary] => 
A new investigational study of Ezetimibe/Simvastatin, the cholesterol-lowering medicine from MSD (known as Merck in US and Canada) showed that at dosage of 10/20 mg, it reduced the incidence of first major vascular events  defined as non-fatal heart attacks or cardiac death, stroke or any revascularization procedure  by a highly statistically significant 16.1 percent compared to placebo (p=0.0010).
                    [DatePublished] => 2010-12-07 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Health And Family
                    [SectionUrl] => health-and-family
                    [URL] => 
                )

            [3] => Array
                (
                    [ArticleID] => 38320
                    [Title] => Fluvastatin XL cuts LDL level with less myalgia
                    [Summary] => 
            
                    [DatePublished] => 2008-01-13 00:00:00
                    [ColumnID] => 136231
                    [Focus] => 0
                    [AuthorID] => 1805110
                    [AuthorName] => Charles C. Chante MD
                    [SectionName] => Opinion
                    [SectionUrl] => opinion
                    [URL] => 
                )

            [4] => Array
                (
                    [ArticleID] => 242152
                    [Title] => CAIs: Reaching optimal cholesterol goals
                    [Summary] => A new class of lipid-lowering therapy could make it easier for patients with high cholesterol levels to reach their optimal cholesterol goals.


Such was the good news relayed by Dr. Werner Katzmann, Ph.D., Far East regional medical director of the Schering-Plough Research Institute, in a lecture during the joint annual convention of the Philippine Society of Hypertension and Philippine Lipid Society recently. 


                    [DatePublished] => 2004-03-11 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

            [5] => Array
                (
                    [ArticleID] => 239583
                    [Title] => Lowering ‘LDL-C’ gets a boost with breakthrough drug
                    [Summary] => A new drug that will reinforce physicians’ existing therapeutic tools in lowering a patient’s low-density lipoprotein (LDL-C) or the bad cholesterol, is now out in the market. 


Ezetimibe, launched by Schering-Plough Phils. Inc., has been shown to have a clinically significant supplementary effect when used with a statin, reducing LDL-C by an additional 25 percent. 


                    [DatePublished] => 2004-02-19 00:00:00
                    [ColumnID] => 133272
                    [Focus] => 0
                    [AuthorID] => 
                    [AuthorName] => 
                    [SectionName] => Science and Environment
                    [SectionUrl] => science-and-environment
                    [URL] => 
                )

        )

)

abtest

MSD's cholesterol-lowering drug cuts atherosclerotic events in CKD patients

July 14, 2011 - 12:00am

Global health care company MSD (known as Merck in the US and Canada) has good news for patients with chronic kidney disease (CKD).

Science and Environment

FDA review backs ezetimibe and simvastatin combination

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | March 6, 2011 - 12:00am

After a year-long review of data from the ENHANCE trial that showed no significant difference in the changes in carotid artery thickness between patients treated with ezetimibe and simvastatin, vs. simvastatin alone,...

Opinion

Hearty news from MSD

December 7, 2010 - 12:00am

A new investigational study of Ezetimibe/Simvastatin, the cholesterol-lowering medicine from MSD (known as Merck in US and Canada) showed that at dosage of 10/20 mg, it reduced the incidence of first major vascular...

Health And Family

Fluvastatin XL cuts LDL level with less myalgia

By YOUR DOSE OF MEDICINE | By Charles C. Chante MD | January 13, 2008 - 12:00am

Opinion

CAIs: Reaching optimal cholesterol goals

March 11, 2004 - 12:00am

A new class of lipid-lowering therapy could make it easier for patients with high cholesterol levels to reach their optimal cholesterol goals. Such was the good news relayed by Dr. Werner Katzmann, Ph.D., Far East...

Science and Environment

Lowering ‘LDL-C’ gets a boost with breakthrough drug

February 19, 2004 - 12:00am

A new drug that will reinforce physicians’ existing therapeutic tools in lowering a patient’s low-density lipoprotein (LDL-C) or the bad cholesterol, is now out in the market. Ezetimibe, launched by Schering-Plough...

Science and Environment